Charles River Laboratories International, Inc. (CRL)

228,38 -3,72 (-1,60%) A partir del 01:51PM EDT. Mercado abierto.

Charles River Laboratories International, Inc.

251 Ballardvale Street
Wilmington, MA 01887
United States
781 222 6000
https://www.criver.com

Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 20.400

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. James C. Foster J.D.	CEO, President & Chairman	2,66M	N/A	1951
Ms. Flavia H. Pease	Corporate Executive VP & CFO	1,66M	N/A	1973
Ms. Birgit Girshick	Corporate Executive VP & COO	1,28M	464,88k	1970
Mr. Joseph W. LaPlume	Corporate Executive Vice President of Corporate Development & Strategy	928,36k	262,98k	1974
Mr. William D. Barbo	Corporate Executive Vice President of Community Relations	1M	399,92k	1961
Mr. Michael Gunnar Knell	Corporate Senior VP & Chief Accounting Officer	N/A	N/A	1977
Prof. Julie Frearson Ph.D.	Corporate Senior VP & Chief Scientific Officer	N/A	N/A	N/A
Mr. Mark Mintz	Corporate Senior VP & Chief Information Officer	N/A	N/A	N/A
Todd Spencer	Corporate Vice President of Investor Relations	N/A	N/A	N/A
Mr. Matthew L. Daniel	Corporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Charles River Laboratories International, Inc., a día 29 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 6; Tablero: 4; Derechos de los accionistas: 8; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.